The two main types of IBD are Ulcerative Colitis and Crohn’s Disease which affect about one in every 250 people in the UK. The research published today in the medical journal, The Lancet, could eventually mean new advice for GPs and patients on how to reduce the risk of developing this dangerous side-effect of bowel disease.
IBD has been known to predispose sufferers to blood clots (thromboembolism) for some time. Clots in the leg veins have a mortality rate of six per cent, rising to as much as 20 per cent if the embolism is in the lungs. Previous research has suggested that most patients who develop thromboembolism do so when their IBD is ‘active’, i.e. has flared up and they are three times more likely to have a blood clot than non-sufferers. This has led to the use of anti-clotting drugs as standard care for patients with active IBD who are admitted to hospital.
The new research at Nottingham was undertaken to find out what the blood-clotting risk is to patients with IBD who manage their flare-ups outside the hospital environment, with medical care from primary care sources like their GP. The team used the UK General Practice Research Database from November 1987 to July 2001 to compare patients with IBD with controls without the disease. They concluded that non-hospitalised sufferers with active IBD were 16 times more likely to develop a blood clot than the general population.
In detail, the researchers analysed 13,756 patients with IBD and 71,672 matched controls, and of these, 139 patients and 165 controls developed a blood clot. Overall, patients with IBD were almost three and a half times more likely to have a blood clot than the controls. At the time of a flare-up however, this increase in risk was much more prominent (eight times). Although the absolute risk of clots was greater for patients in hospital, this relative risk at the time of a flare-up was higher during non-hospitalised periods (when patients were at 16 times the risk of their non-hospitalised controls) than during hospitalised periods (when the risk was three times that of other hospitalised patients).
Dr Matthew Grainge, Lecturer in the University’s Department of Community Health Sciences said:
“Inflammatory bowel disease was associated with a roughly three-fold increase in the risk of venous thromboembolism. Compared with the general population while ambulatory, the risk of venous thromboembolism was increased about 16-fold for non-hospitalised patients with active inflammatory bowel disease. Despite the low absolute risks during non-hospitalised periods, these results suggest that active inflammatory bowel disease in ambulatory patients might be a far greater risk factor for venous thromboembolism than previously recognised.”
Dr Grainge’s co-researcher, Dr Tim Card concluded:
“We believe that the medical profession needs to recognise the increased risk in people with inflammatory bowel disease when assessing the likelihood of venous thromboembolism and to address the difficulty of reducing this risk in patients with a flare who are not admitted to hospital... Such strategies to achieve a reduction in risk might include those used for inpatients such as brief courses of low-molecular weight heparin or perhaps newly available oral anticoagulants.”
Commenting on the research, Dr Geoffrey C Nguyen, Mount Sinai Hospital Inflammatory Bowel Disease Centre, University of Toronto, Canada, and Johns Hopkins Division of Gastroenterology and Hepatology, Baltimore, MD, USA; and Dr Erik L Yeo, University Health Network Thrombosis Clinic, University of Toronto, Canada, said:
“We believe that the clinical efficacy and cost-effectiveness of pharmacological prophylaxis in the population with inflammatory bowel disease should be proven before it is routinely recommended during acute flares. The ascertainment of efficacy data through clinical trials might, however, be a formidable challenge given that the absolute risk of venous thromboembolism is low and a sample size of thousands of people with inflammatory bowel disease during active flares might be required.
“A pragmatic initial approach to reduction of the rates of morbidity and mortality resulting from venous thromboembolism in ambulatory patients with inflammatory bowel disease would be non-pharmacological thromboprophylaxis, including patients’ education and awareness of risk and signs and symptoms of venous thromboembolism, and use of support stockings.”
Emma Rayner | EurekAlert!
The birth of a new protein
20.10.2017 | University of Arizona
Building New Moss Factories
20.10.2017 | Albert-Ludwigs-Universität Freiburg im Breisgau
University of Maryland researchers contribute to historic detection of gravitational waves and light created by event
On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...
Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.
Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....
Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).
When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...
Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.
How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...
Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.
It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...
17.10.2017 | Event News
10.10.2017 | Event News
10.10.2017 | Event News
20.10.2017 | Information Technology
20.10.2017 | Materials Sciences
20.10.2017 | Interdisciplinary Research